Ophthalmology | Phase I Developments | UNITED STATES

Allakos

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Allakos Announces a Presentation of Antolimab in Patients with Severe Allergic Conjunctivitis at the 2020 ASCRS Virtual Annual Meeting

Lead Product(s): Antolimab

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 11, 2020

Details:

The presentation will showcase results from Phase 1b Study of an Anti-Siglec-8 Monoclonal Antibody, Antolimab (AK002), in Severe Allergic Conjunctivitis.

Adverum Biotechnologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Adverum Biotechnologies Reports Interim Data from Cohorts 1-3 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

Lead Product(s): AAV.7m8-aflibercept

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I Product Type: Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

In the OPTIC Phase 1 Trial ADVM-022 continued to show robust efficacy. Long-term durability beyond 1 year from a single IVT injection with zero rescue injections in Cohort 1.

Adverum Biotechnologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Adverum Biotechnologies Announces Virtual Presentations of Data through ASGCT and ARVO

Lead Product(s): AAV.7m8-aflibercept

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I Product Type: Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 30, 2020

Details:

Adverum Biotechnologies to present data of ADVM-022 Intravitreal Gene Therapy for Neovascular AMD - results from the Phase 1 OPTIC Study.

Adverum Biotechnologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Adverum Biotechnologies Doses First Patient in Cohort 4 of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

Lead Product(s): AAV.7m8-aflibercept

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I Product Type: Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

Details:

Patients in Cohort 4 are receiving a single intravitreal injection of gene therapy candidate ADVM-022 and are receiving steroid eye drop prophylaxis for six weeks (same as Cohort 3).

Ocular Therapeutix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Ocular Therapeutix Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial

Lead Product(s): OTX-TKI

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

Details:

Two cohorts of six subjects each have been enrolled, a lower dose cohort of 200 ?g and a higher dose cohort of 400 ?g.

Aerpio Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort

Lead Product(s): Razuprotafib,Prostaglandin

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2020

Details:

The Phase 1b trial is a randomized, double-masked study designed to assess increasing concentrations of AKB-9778 dosed topically as eye drops.

Adverum Biotechnologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Adverum Biotechnologies Unveils Interim Data from OPTIC Trial

Lead Product(s): Aflibercept

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I Product Type: Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 08, 2020

Details:

ADVM-022 demonstrated a robust efficacy signal and evidence of a dose response. In both cohorts combined, 10 of 12 (83%) patients remain rescue-injection-free.

Adverum Biotechnologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Adverum Biotechnologies to Present Additional Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the An...

Lead Product(s): Aflibercept

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I Product Type: Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

Adverum Biotechnologies is conducting a phase1 study of Intravitreal gene therapy with ADVM-022 for Neovascular AMD (OPTIC Trial).

Adverum Biotechnologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD

Lead Product(s): Aflibercept

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I Product Type: Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 12, 2020

Details:

OPTIC phase 1 trial progressing with plans to complete patient dosing in cohort three, begin enrollment in cohort four in 1Q20. IND application planned for ADVM-022 in diabetic retinopathy in 1H20.

Gemini Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration

Lead Product(s): GEM103

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

The company looking forward to topline data from this study and the potential to initiate a Phase 2 study supported by the CLARITY natural history study data.

Find

Find Ophthalmology Drugs in Phase I Clinical Development in UNITED STATES

United States

A collaboration with SCORR Marketing

Product Type

Companies

Allakos

Allakos Announces a Presentation of Antolimab in Patients with Severe Allergic Conjunctivitis at the 2020 ASCRS Virtual Annual Meeting

Adverum Biotechnologies

Adverum Biotechnologies Reports Interim Data from Cohorts 1-3 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

Adverum Biotechnologies

Adverum Biotechnologies Announces Virtual Presentations of Data through ASGCT and ARVO

Adverum Biotechnologies

Adverum Biotechnologies Doses First Patient in Cohort 4 of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

Ocular Therapeutix

Ocular Therapeutix Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial

Aerpio Pharmaceuticals

Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort

Adverum Biotechnologies

Adverum Biotechnologies Unveils Interim Data from OPTIC Trial

Adverum Biotechnologies

Adverum Biotechnologies to Present Additional Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the An...

Adverum Biotechnologies

Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD

Gemini Therapeutics

Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration